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Abstract: 
Right ventricular (RV) dysfunction has been associated with adverse clinical outcomes in 
patients with heart failure (HF). Cardiac resynchronization therapy (CRT) improves left 
ventricular (LV) size and function in patients with markedly abnormal ECG QRS 
duration.  However, relationship of baseline RV function with response to CRT has not 
been well described. In this study we aim to investigate the relation of baseline RV 
function with response to CRT as assessed by change in LV ejection fraction (EF). A 
systematic search of studies published between 1966 to May 31, 2015 was conducted 
using Pub Med, CINAHL, Cochrane CENTRAL and the Web of Science databases. 
Studies were included if they have reported a) parameters of baseline RV function 
[tricuspid annular plane systolic excursion (TAPSE) or RV ejection fraction (RVEF) or 
RV basal strain or RV fractional area change (FAC)] and b) LVEF before and after CRT. 
Random-effects meta-regression was used to evaluate the effect of baseline RV function 
parameters and change in LVEF. Sixteen studies (N=1764) were selected for final 
analysis. Random-effects meta-regression analysis showed no significant association 
between the magnitude of the difference in EF pre and post CRT with baseline TAPSE 
(beta 0.005, p 0.989); baseline RVEF (beta 0.270, p 0.493); baseline RVFAC (beta - 
0.367, p 0.06); baseline basal strain (beta -0.342, p= 0.462) after a mean follow up period 
of 10.5 months. In conclusion, baseline RV function as assessed by TAPSE, FAC, basal 
strain or RVEF, does not determine response to CRT as assessed by change in LVEF.  
 
Key words: Right ventricle function, Cardiac resynchronization therapy, Left ventricular 
ejection fraction 
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INTRODUCTION 
     Right ventricular (RV) function is an independent prognostic marker for heart failure 
(HF) patients and; also plays an important role in determining the response to medical 
therapy in patients with HF [1, 2]. Recently, it has been suggested that baseline 
echocardiographic parameters of RV function could be helpful in identifying patients 
who respond more favorably to Cardiac resynchronization therapy (CRT) [3, 4]. 
However, studies have reported conflicting results, and the relationship of baseline RV 
function with response to CRT remains unclear [3-19]. In this study, we performed a 
meta-analysis of published studies and investigated the relationship of various baseline 
echocardiographic parameters of RV function with response to CRT, as assessed by 
change in LV ejection fraction (EF). 
METHODS 
     A systematic review of the literature was performed according to the PRISMA 
(Preferred Reporting Items for Systematic reviews and Meta-Analyses) statement [20]. 
We systematically searched PubMed, CINAHL, Cochran CENTRAL, Embase, Scopus 
and Web of Science databases for all studies that reported parameters of RV function at 
baseline and LVEF before and after CRT implantation. All relevant combinations of the 
following keywords related to CRT were included in the search: RV function, tricuspid 
annular plane systolic excursion (TAPSE), RV diameters, RV short axis diameter, RV 
long axis diameter, RV fractional area change (FAC), LVEF. The search was conducted 
from the inception of each database to May 31, 2015. No language or age restrictions 
were applied. Pertinent trials were also searched in clinicaltrials.gov and in the 
proceedings of major international cardiology meetings (American College of 
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Cardiology, American Heart Association, European Society of Cardiology, Heart Rhythm 
Society). Studies were included if they met each of the following three criteria: 1) human 
studies with participants of any age requiring CRT for any indication, 2) reported at least 
one parameter of baseline RV function [TAPSE, and/or RVEF, and/or RV long axis 
diameter, and/or RV basal strain and/or RVFAC] and 3) reported LVEF before and after 
CRT. Two independent reviewers (AS, SG) screened the titles and abstracts for 
relevance. Discrepancies between reviewers were discussed until consensus was reached. 
The manuscripts of selected titles/abstracts were reviewed for inclusion and authors were 
contacted if additional data were needed. Using the above mentioned selection criteria, 
these two reviewers independently determined the articles to be included and excluded, 
and data from the relevant articles were extracted using pre-defined extraction forms. 
Any disagreements in data extraction were discussed until consensus was reached.  
          In this analysis, Review Manager Version 5.1 (The Nordic Cochrane Center, The 
Cochrane Collaboration, 2008, Copenhagen) was used. A random-effects model with 
inverse variance weighting was used to calculate pooled mean difference in LVEF and 
corresponding confidence interval. Heterogeneity between studies was assessed using 
Cochrane’s Q test and I2 statistic, which denotes the percentage of total variation across 
studies that is a result of heterogeneity rather than chance. Heterogeneity was considered 
significant if the p value was less than 0.05. Publication bias was assessed by Begg’s test 
and Egger’s regression test.  The influence of individual studies was examined by 
removing each study at a time to assess the degree to which meta-analysis estimate 
depends on a particular study (exclusion sensitivity analysis). Open Meta-Analyst 
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software was utilized to perform random-effects meta-regression to evaluate the effect of 
baseline RV function parameters on change in LVEF [21]. 
RESULTS 
     We identified seventeen studies, which reported parameters of baseline RV function 
and LVEF (Figure 1) [3-19]. One study was not included in the final analysis, as it did 
not provide data in terms of absolute number (and standard deviation) for baseline RV 
function parameters and LVEF before and after CRT [19]. Sixteen studies were selected 
for final analysis [3-18]. Details of the studies and baseline characteristics are 
summarized in Table 1 and 2.  
     Pooled analysis of sixteen studies reporting LVEF and RV function revealed that CRT 
led to an absolute increase of 5.82 % (95% CI 4.23 – 7.41) in mean LVEF (Figure 2). 
There was significant heterogeneity across the studies (p <0.001, I2 =91%). Sensitivity 
analysis did not demonstrate any significant change in effect size with exclusion of any 
particular study.  
     Pooled analysis of the ten studies that reported the effect of baseline TAPSE on ∆ 
LVEF (N=1368) showed that CRT improved LVEF by 5.96 % (95% CI 4.64 – 7.29) 
(supplementary figure 1). Random-effects meta-regression analysis showed no significant 
association between the magnitude of the difference in LVEF pre and post CRT with 
baseline TAPSE (beta 0.005, p = 0.989) (Figure 3). Similar improvement in LV function 
was noted after pooling the studies presenting baseline RVEF [5.91% (95% CI 0.06-
11.76), (N=168), (supplementary figure 2)], RV FAC [6.26% (95% CI 4.50 – 8.03), 
(N=1245), (supplementary figure 3)], RV basal strain [6.08 %, (95% CI 2.37 – 9.79), 
(N=191), (supplementary figure 4)] and RV long axis diameter [5.18%, (95% CI 2.96-
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7.41), (N=216), (supplementary figure 5)]. Meta-regression revealed that baseline RVEF 
(beta 0.270, p = 0.493) (Figure 4) and baseline RV FAC (beta - 0.367, p = 0.06) (Figure 
5) did not significantly impact ∆ LVEF. Similarly, there was no significant association 
between baseline RV basal strain (beta -0.342, p= 0.462) (Figure 6) and RV long axis 
diameter (beta -.0.222, p=0.423) (Figure 7) with ∆ LVEF. 
DISCUSSION 
     Our results show that there is no significant association between baseline RV function 
and response to CRT as assessed by change in LVEF. There was no statistically 
significant relationship of the magnitude of the difference in pre- and post-CRT LVEF 
with any baseline echocardiographic parameters of RV function. Thus, assessment of RV 
function might not be useful in selecting patients for improvement in LVEF after CRT. 
     Previous studies have reported conflicting effects of baseline RV function on response 
to CRT. Almost a decade ago, in a small study (n=15), Boriani et al reported that RV 
dysfunction as assessed by radionuclide angiography did not determine relative benefits 
of CRT [7]. Later, Burri et al, reported that patients with baseline RV dysfunction 
(defined as RVEF≤35% by radionuclide angiography) were less likely to respond to CRT 
as assessed by improvement in NYHA classification, 6 minute walking distance and 
LVEF after a mean follow up of 9 months [8]. However, the presence of reduced baseline 
RVEF (assessed radionuclide angiography) alone cannot be used to exclude patients from 
CRT, as 47% of patients with reduced RVEF still showed improvement in NYHA 
classification [8]. In post hoc analysis of patients from Cardiac Resynchronization in 
Heart Failure (CARE-HF) trial, Damy et al reported that though presence of baseline RV 
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dysfunction correlated with overall poor prognosis, it does not predict response to 
response to CRT [19]. 
     While understanding the relation of baseline RV function and response to CRT, it is 
important to distinguish between ‘outcome’ and ‘response’ to CRT. As shown by Damy 
and colleagues, the presence of baseline RV dysfunction among patients who received 
CRT is associated with poor clinical outcomes [19]. This could be partly due to the fact 
RV dysfunction itself is an independent prognostic marker and associated with worse 
clinical outcomes in patients with HF [1, 2].  However, patients with or without RV 
dysfunction appeared to respond to CRT to similar extent [19]. Thus, echocardiographic 
parameters of baseline RV function might not be helpful in selecting patients for CRT 
therapy, and therefore this therapy should not be denied to patients with baseline RV 
dysfunction.  
     This is the first meta-analysis to evaluate the relationship of baseline RV function with 
response to CRT. Echocardiography is the most common technique to assess RV function 
in clinical practice. Most of the studies included in our meta-analysis have used TAPSE 
as a measure of RV function; TAPSE is a relatively simple echocardiographic measure, 
which represents RV longitudinal function, which has been shown to have a good 
correlation with more precise measures of RV systolic function, such as radionuclide 
quantification of RVEF [22]. However, a major limitation of TAPSE is that it only 
measures the contribution of the RV free wall to predict RV global systolic function [23, 
24]. A more global measure of RV systolic function is FAC, which has shown to 
correlate well with cardiac magnetic resonance imaging (MRI)-derived RVEF [25]. 
However, FAC is considered as more a measure of RV response to afterload than a 
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measure of contractility. However, due to asymmetric shape and complex geometry, use 
of a single echocardiographic parameter might not be sufficient to comprehensively 
assess RV function. Previous studies have used one or two echocardiographic parameters 
of RV function. To overcome this limitation, however, we have used various 
echocardiographic parameters of RV function to analyze the relationship of baseline RV 
function with response to CRT in 1764 patients from 16 studies with a mean follow up 
period of 10.5 months. 
     There are several limitations to our study. First, studies used in our analysis did not 
used advanced cardiac imaging modalities to evaluate RV function. The RV has a 
complex geometry and is volume dependent affected by preloading conditions, which 
pose a challenge in accurately determining the RV function [22]. Even so, with 
echocardiography being inexpensive and readily available, it remains by far the most 
widely used modality to measure RV function, which is why we focused on it for 
assessment of RV function in this meta-analysis. Since one echocardiographic measure 
might not accurately represent true RV function, we used multiple parameters of RV 
function. Importantly, our results were consistent across all parameters of RV function, 
including TAPSE and FAC, which have been reported to correlate well with measures of 
RV function obtained by cardiac MRI. Second, as mentioned above, we could not include 
a few studies in our analysis, as these studies did not report data in terms of absolute 
number for baseline RV function parameters and LVEF before and after CRT therapy, 
including the post hoc analysis of CARE-HF trial. However, results of sub-analysis of 
CARE-HF data are in agreement with our findings and its inclusion might if anything 
have made our findings stronger [19].  
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FIGURE LEGENDS: 
 
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) flow sheet 
 
Figure 2. Forest plot for change in LVEF with CRT for all studies. 
 
Figure 3. Random-effects meta-regression analysis depicting the relationship between 
mean differences in left ventricular ejection fraction (∆ LVEF) (on Y axis) and baseline 
TAPSE on (X-axis). Each included study is represented by a circle, the size of which is 
proportional to its respective weight in the analysis. The line indicates the predicted 
effects (regression line). There was no significant association [β = 0.005, P = 0.989]. 
 
Figure 4. Random-effects meta-regression analysis depicting the relationship between 
mean differences in left ventricular ejection fraction (∆ LVEF) (on Y axis) and baseline 
right ventricular ejection fraction (on X-axis). Each included study is represented by a 
circle, the size of which is proportional to its respective weight in the analysis. The line 
indicates the predicted effects (regression line). There was no significant association [β = 
0.270, P = 0.493]. 
 
Figure 5. Random-effects meta-regression analysis depicting the relationship between 
mean differences in left ventricular ejection fraction (∆ LVEF) (on Y axis) and baseline 
right ventricular fractional area change (RV FAC on X-axis). Each included study is 
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represented by a circle, the size of which is proportional to its respective weight in the 
analysis. The line indicates the predicted effects (regression line). There was no 
significant association [β = - 0.367, P = 0.06]. 
 
Figure 6. Random-effects meta-regression analysis depicting the relationship between 
mean differences in left ventricular ejection fraction (∆ LVEF) (on Y axis) and baseline 
right ventricular basal strain (on X-axis). Each included study is represented by a circle, 
the size of which is proportional to its respective weight in the analysis. The line indicates 
the predicted effects (regression line). There was no significant association [β = - 0.342, P 
= 0.462]. 
 
Figure 7. Random-effects meta-regression analysis depicting the relationship between 
mean differences in left ventricular ejection fraction (∆ LVEF) (on Y axis) and baseline 
right ventricular long axis diameter (on X-axis). Each included study is represented by a 
circle, the size of which is proportional to its respective weight in the analysis. The line 
indicates the predicted effects (regression line). There was no significant association [β = 
- 0.222, P = 0.423]. 
 
 
 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 17
Supplementary figures: 
Supplementary figure 1. Forest plot for change in LVEF with CRT for studies reporting 
baseline TAPSE. 
Supplementary figure 2. Forest plot for change in LVEF with CRT for studies reporting 
baseline RVEF. 
Supplementary figure 3. Forest plot for change in LVEF with CRT for studies reporting 
baseline FAC. 
Supplementary figure 4. Forest plot for change in LVEF with CRT for studies reporting 
baseline basal strain. 
Supplementary figure 5. Forest plot for change in LVEF with CRT for studies reporting 
baseline RV long axis diameter. 
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Table 1. Baseline characteristics of studies included in analysis 
First Author (Year) N Follow 
up 
(months) 
NYHA 
III/IV 
Mean 
QRS 
duration 
(msec) 
         RV function parameters 
 
LVEF LVEF at 
end of 
follow 
up  
FAC 
 
TAPSE 
 
RVEF 
 
RVLA 
 
Basal 
Strain 
Abu Sham’a [2012]
a
 35 26.5 59%/- 173 ± 33    +            -            -            -             - 22 ± 5% 24 ± 7% 
Abu Sham’a [2012]
b
 158 26.5 52%/- 161 ± 30    +            -            -            -             - 25 ± 7% 30 ± 9% 
Bleeker [2005] 56 6 89%/11% 176 ± 30    -             -            -            +             - 19 ± 6% 26 ± 8% 
Boriani [2005] 15 3 80%/13% 189 ± 26    -             -            +            -             - 21 ± 9% 29 ±13% 
Burri [2010] 44 9 70%/30% 162 ± 25    -             -            +            -             - 24 ± 8% 29 ±12% 
D'Andrea [2009]
c
 29 6 82%/18% 149 ± 22    -             +            -            +             - 30 ± 5% 38 ±4% 
D'Andrea [2009]
d
 41 6 82%/19% 149 ± 22    -             +            -            +             - 31 ± 3% 38 ± 5% 
D'Andrea [2009]
e
 21 6 82%/18% 149 ± 22    -             +            -            +             - 31 ± 3% 33 ± 4% 
D'Andrea [2009] 
f
 19 6 82%/19% 149 ± 22    -             +            -            +             - 29 ± 5% 32 ± 4% 
Donal [2008] 50 3 68%/32% 163 ± 28    -             +            -            +             + 22 ± 6% 27 ± 9% 
Eder [2007] 
g
 16 6 - -    -             -             +            -             - 22 ± 2% 20 ± 1% 
Eder [2007] 
h
 12 6 - -    -             -             +            -             - 20 ± 2% 30 ± 3% 
Esmaeilzadeh[2011] 
i
 16 0.25 - 143 ± 19    +            +            -            -             + 19 ± 5% 24 ±19% 
Esmaeilzadeh[2011] 
j
 20 0.25 - 144 ± 15    +            +            -            -             + 19 ± 6% 23 ±8% 
Knappe [2013] 63 12 0 -    +            -            -            -             - 24 ± 5% 37 ± 5% 
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a: Moderate to severe TR   b:  No or mild TR c: Responder ischemic DCM, d: Responder idiopathic DCM, e: Non responder Ischemic DCM, f: 
Non responder Idiopathic DCM, g: With increase in LVEF, h: Without increase in LVEF, i: Pt with RVMD, j: Pt without RVMD k: Responders, l: 
Non responders, m: Patient with events, n: Patient without events, o: Responders, p: non-responders  
-  =No information available 
Kusiak [2012] 57 3 - 184 ± 28    -            +            -            -             - 22 ± 5% 26 ± 5% 
Leong [2013] 738 6 68%/9% 155 ± 33    +           +            -            -             - 26 ± 8% 32 ±10% 
Praus [2012] 
k
 38 15 - 193 ± 28    -            +            -            -             - 22 ± 5% 33 ±12% 
Praus [2012]  
l
 19 15 - 195 ± 42    -            +           -            -             - 22 ± 7% 25 ±8% 
Sade [2013] 
m
 31 32 - 142 ± 21    -            +            -            -            + 21 ± 5% 25 ± 8% 
Sade [2013] 
n
 74 32 - 148 ± 22    -            +           -            -             - 24 ± 6% 35 ±11% 
Scuteri [2009] 44 6 - 157 ± 25    +           +            -            -             - 23 ± 5% 31 ±9% 
Szulik [2011] 90 18 64%/36% 176 ± 29    +           +           -             -              - 25 ± 8% 31 ±11% 
Vitarelli [2011] 
o
 50 6 -  189 ± 24    +           +           +            -             - 19 ± 11% 32 ±15% 
Vitarelli [2011] 
p
 31 6 - 171 ± 22    +           +           +            -             - 22 ± 8% 25 ±7% 
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Table 2. Baseline patient characteristics in the studies included in the analysis 
First Author (Year) Mean 
age (yr.) 
Male  IC/NIC  
Heart 
Failure  
LBBB/ 
RBBB  
DM  HTN  HLD  Smoker  Beta-
blocker  
ACE  Spironolact
one/Loop 
Diuretic  
Abu Sham’a  [2012]
a
 69 ± 12 83% 71%/29% 43%/ 14% - - - - - - - 
Abu Sham’a  [2012]
b
 69 ± 10 87% 70%/30% 52%/ 13% - - - - - - - 
Bleeker [2005] 64 ± 11 79% 52%/48% - - - - - 50% 52% - /82% 
Boriani [2005] 62 ± 5 80% 47%/53% - - - - - - - - 
Burri [2010] 72 ± 9 80% 57%/43% 73%/ 9% 12% - - - 82% 95% - /80% 
D'Andrea [2009]
c
 57 ± 11 52% 100%/0 -  46% 35% 58% 44% 86% 95% 53%/95% 
D'Andrea [2009]
d
 55+/-8 55% 0/100% - 32% 33% 53% 35% 82% 94% 58%/96% 
D'Andrea [2009]
e
 57+/-11 52% 100%/0 - 46% 35% 58% 44% 86% 95% 53%/95% 
D'Andrea [2009] 
f
 55 ± 8 55% 0/100% - 32% 33% 53% 35% 82% 94% 58%/96% 
Donal [2008] 67 ± 10 75% 45%/55% - - - - - - - - 
Eder [2007] 
g
     - 67% 20%/80% -  - - - - - - - 
Eder [2007] 
h
 - 77% 23%/77% - -  - - - - - - 
Esmaeilzadeh [2011] 
i
 62 ± 10 58% 48%/56% 53%/ 6% - - - - - - - 
Esmaeilzadeh [2011] 
j
 57 ± 13 58% 50%/50% 53%/ 7% - - - - - - - 
Knappe [2013] 64 ± 12 81% 51%/ - 78%/ - - - - - 84% 83% 43%/84% 
Kusiak [2012]  66 ± 9 95% 72%/ - - 40% 63% 77% 23% 96% 86%  - /88% 
Leong [2013] 67 78% 60%/ - 68%/ - 21% - - - 71% 89% 47%/83% 
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Praus [2012] 
k
 67 ± 9 - 47%/47% - - - - - - - - 
Praus [2012]  
l
 67 ± 9 - 74%/21% - - - - - - - - 
Sade [2013] 
m
 60 ± 11 82% 71%/ - 68%/ 13% - - - - 83% 63% 83%/87% 
Sade [2013] 
n
 63 ± 11 81% 53%/ - 72%/ 5% - - - - 92% 92% 71%/84% 
Scuteri  [2009] 59 ± 10 81% 31%/ - - - - - - 83% 95% 70%/100%
Szulik [2011]  57 ± 9 62% 41%/59% 88%/ - 22% - 52% - 100% 88% 84%/89% 
Vitarelli [2011] 
o
 65 ± 13 64% 58%/42% - - - - - 70% 93% - 
Vitarelli [2011] 
p
 63 ± 16 68% 68%/32% - - - - - 84% 86% - 
a: Moderate to severe TR   b:  No or mild TR c: Responder ischemic DCM, d: Responder idiopathic DCM, e: Non responder Ischemic DCM, f: 
Non responder Idiopathic DCM, g: With increase in LVEF, h: Without increase in LVEF, i: Pt with RVMD, j: Pt without RVMD k: Responders, l: 
Non responders, m: Patient with events, n: Patient without events, o: Responders, p: non-responders  
IC: Ischemic Cardiomyopathy; NIC: Non-ischemic cardiomyopathy; LBBB: Left bundle branch block; RBBB: Right bundle branch block; DM: 
Diabetes mellitus; HTN: Hypertension; HLD: Hyperlipidemia; ACE: Angiotensin converting enzyme inhibitors 
-  =No information available 
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Figure 1. PRISMA Flowsheet  
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